Platelet secretion plays a key role in thrombosis, thus the platelet secretory machinery offers a unique target to modulate hemostasis. We report the regulation of platelet secretion via phosphorylation of SNAP-23 at Ser95. Phosphorylation of this t-SNARE occurs upon activation of known elements of and SNARE complex formation; but, had no effect on platelet morphology or other metrics of platelet activation. Consistently, SNAP-23 phosphorylation enhanced membrane fusion of SNARE-containing proteoliposomes. In vivo studies with IKK inhibitors or platelet-specific IKKβ knockout mice showed that blocking IKKβ activity significantly prolonged tail-bleeding times suggesting that currently available IKK inhibitors may affect hemostasis.
, and Protein Kinase C (PKC) isoforms).
In platelets, PKC phosphorylates SNAP-23 and syntaxin-4 modulating SNARE complex formation. 20 In neurons, SNAP-25 phosphorylation on Ser187 by PKC promotes syntaxin-1 binding. 21 Hepp et al. 22 For personal use only. on October 4, 2017. by guest www.bloodjournal.org From demonstrated phosphorylation of SNAP-23, on Ser95 and Ser120, in mast cells and in thrombinactivated platelets. In mast cells, SNAP-23 is phosphorylated by IκB kinase (IKK), which is important for secretion 23 . Conversely, PKA phosphorylation of SNAP-25 or syntaxin disrupts interactions. 24 These reports illustrate the varied modes by which kinases control SNAREs and thus secretion.
Liu et al. 25 showed that IκB is phosphorylated in activated platelets; while, Malavar et al. 26 showed that inhibiting IKK affects platelet function. These data suggest a role for IKK in platelets, but a mechanistic understanding is lacking. In this manuscript, we asked whether IKK regulates SNAP-23, and thus secretion from platelets and whether IKK could be targeted for anti-thrombotic therapeutics.
We show that IKK phosphorylates SNAP-23 in response to a number of agonists and that phosphorylation is important for SNARE complex formation and membrane fusion. We further demonstrate that IKK is part of the activation cascades in platelets and that targeting IKK affects hemostasis in vivo. Our data demonstrate that, in addition to their anti-inflammatory and anti-cancer properties, IKK inhibitors may be worth exploring as anti-thrombotic agents.
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Methods:
Antibodies and Reagents: The anti-endobrevin/VAMP-8 antibody 27 and anti-cellubrevin/VAMP-3, antisyntaxin-2, -syntaxin-4, and -SNAP-23 antibodies were as described. 28 The anti-SNAP-23
phosphorylation-site-specific antibody was previously characterized. 22 were from Calbiochem (San Diego, CA). Apyrase, phorbol 12-myristate 13 acetate (PMA), genistein, prostaglandin I 2 (PGI 2 ), BAY 11-7082, BMS-345541, TPCA-1, and wedelolactone were from Sigma.
Rottlerin was from Biomol (Plymouth, PA). Purified IKK was from Invitrogen and PKCα was from SignalChem (Richmond, BC). Type I collagen and thrombin were from Chrono-log (Havertown, PA).
U73122 and U73343 were from Alexis Biochemicals (San Diego, CA). Other reagents were of analytical grade.
Mice and Genotyping: PF4-Cre + mice 29 were from Dr. Radek Skoda (University Hospital Basel, Switzerland) and were genotyped as described. 12 
Preparation of Platelets:
Mouse blood was collected from a ventricle and the citrated (0.38%) blood was mixed with PBS, pH 7.4 and incubated with PGI 2 (10 ng/mL; 5min), followed by centrifugation at
For personal use only. on October 4, 2017. by guest www.bloodjournal.org From 7 237 x g for 10 min at room temperature (RT). Platelet-rich plasma (PRP) was recovered and platelets were pelleted at 483 x g for 10 min at RT. The pellets were resuspended in HEPES/Tyrode buffer (HT; 20 mM HEPES/KOH, pH 6.5, 128 mM NaCl, 2.8 mM KCl, 1 mM MgCl 2 , 0.4 mM NaH 2 PO 4 , 12 mM NaHCO 3 , 5 mM D-glucose) supplemented with 1 mM EGTA, 0.37 U/mL apyrase, and 10 ng/mL PGI 2 .
Platelets were washed and resuspended in HT(pH 7.4) without EGTA, apyrase, or PGI 2 . Platelets were counted with a Z2 Coulter Particle Analyzer (Beckman/Coulter, Fullerton, CA) and adjusted to the indicated concentrations.
Washed human platelets were prepared as described. 31 PRP was isolated in the presence of apyrase (0.37 U/mL) and PGI 2 (10 ng/mL) by centrifugation at 150 x g for 10 min at RT. PRP was centrifuged at 900 × g for 10 min and platelets were resuspended in HT containing 1 mM EGTA, apyrase, and PGI 2 . Platelets were washed and resuspended in HT (pH 7.4) without EGTA, apyrase, or
Measurement of Platelet Granule Cargo Release: Platelets were labeled with 0.4 µCi/mL [ 3 H]5-HT (serotonin; Perkin-Elmer, Waltham, MA) for 1 hr at RT. After washing, the platelets were resuspended in HT (pH 7.4) and CaCl 2 (0.7 mM final) prior to stimulation with thrombin (0.05 U/mL; Chrono-log) for the indicated times. Hirudin (0.1 U/mL; Sigma) was added to stop the reaction. Platelets were incubated with BMS-345541 (5 μM) or TPCA-1 (0.5 μM) prior to stimulation. The samples were separated by centrifugation at 13,800 x g for 1 min, the supernatants were recovered, and the pellets were lysed with 1% Triton X-100 in PBS. Equal volumes of both fractions were assayed for [ 3 H]5-HT (serotonin) for dense granules, platelet factor 4 (PF4) for α-granules, and β -hexosaminidase for lysosomes as described.
28,32
Preparation of SNARE-Containing Proteoliposomes: All lipids were from Avanti Polar Lipids (Alabaster, AL). Reconstitution of v-SNARE and t-SNARE vesicles was as described. 33 v-SNAREs were reconstituted using a mix of 27% 1-palmitoyl-2-oleoyl-phosphatidylethanolamine (PE), 55% 1-palmitoyl, 2-oleoyl phosphatidylcholine (PC), 15% 1,2-dioleoyl phosphatidylserine (PS), 1.5% N- (7- For personal use only. on October 4, 2017. by guest www.bloodjournal.org From 8 nitro-2-1,3-benzoxadiazol-4-yl)-1,2-dipalmitoyl phosphatidylethanolamine (NBD-PE, donor), and 1.5% N-(lissamine rhodamine B sulfonyl)-1,2-dipalmitoyl phosphatidylethanolamine (Rhodamine-PE, acceptor). t-SNAREs were reconstituted in 30% PE, 55% PC and 15% PS. v-SNARE (VAMP-8) and t-SNARE (SNAP-23 + syntaxin-2) vesicles were reconstituted to give ~60 copies and ~95 copies per vesicle, respectively. Syntaxin-2 was a surrogate for syntaxin-11, as we cannot produce recombinant syntaxin-11 with the appropriate acylation.
For fusion assays, 10 μL t-SNARE vesicles were incubated with 0.5 mM ATP, 10 mM MgCl 2 , and increasing IKK (0-2.0 μg/reaction) at RT. v-SNARE vesicles were incubated separately at RT. After 60 min, v-and half of the t-SNARE vesicles were mixed in 25 mM HEPES pH 7.4, 100 mM KCl, 1 mM DTT and fusion was monitored at 37°C. Calcium (1 mM final) was added at t=20 min. The increase in NBD fluorescence was measured using a Bio-TEK FLx800 Microplate Fluorescence Reader and KC4 software with data acquisition every 1.5 min. After 60 min, 15 μL of 5% n-dodecyl-β-D-octylglucoside was added to obtain the maximum fluorescence. Fusion was plotted as the percent of maximum fluorescence over time. Some aliquot of t-SNAREs were analyzed by immunoblotting using antiphospho-Ser95 and anti-SNAP-23 antibodies. For inhibitor studies, 5 μM BMS-345541 or 0.5 μM TPCA-1 were added to the t-SNARE mixture containing 1.0 μg IKK and fusion was monitored after 60 min.
Immunoblotting: Platelet proteins were separated by SDS-PAGE and transferred to Immobilon-P PVDF membranes (Millipore Corp., Bedford, MA). They were then probed with the indicated primary antibodies and visualized with an appropriate alkaline phosphatase-coupled secondary antibody using Immunoprecipitation: Immunoprecipitation was carried out as described. 34 Platelets were incubated in presence or absence of inhibitor and activated with thrombin (0.1 U/mL) followed by lysis with 2x lysis HT(pH 7.4). The labeled platelets were preincubated with inhibitors and then stimulated with thrombin.
The reactions were stopped with SDS-PAGE sample buffer and the labeled proteins were separated by SDS-PAGE and visualized by phosphorimaging using the Typhoon 9400 Imager.
Bleeding Time Measurements: BMS-345541 was administered by gavage to C57Bl6/J male mice (18-22 g ). BMS-345541 was formulated as a 2 mg/mL stock in 3% Tween 80. 35 Ten mg/kg of drug per mouse was administered 2 hr prior to bleeding-time measurement. The mice were sedated with ketamine/xylazine and their tails were transected 3 mm from the tip. The tail was placed in saline at 37°C and the time to blood flow cessation was measured. Clotting was not considered complete until bleeding had stopped for 1 min. When required, measurements were terminated at 10 min. Previous studies showed that IκB is phosphorylated on Ser32 upon platelet activation, suggesting that IKK is activated in stimulated platelets. 25, 26 Consistently, we detected the three subunits of IKK (α, β, γ/NEMO) as well as an upstream activator, the CBM complex (CARMA1, Bcl10 and MALT1) in both human and mouse platelets ( Figure 2A ). IκB phosphorylation occurred upon platelet activation with thrombin and was blocked by BMS-345541, TPCA-1, and BAY 11-7082 ( Figure 2B , C).
IKK is Important for Platelet Secretion: SNAP-23 phosphorylation temporally correlated with dense granule release 38 and BAY 11-7082 treatment altered ATP release and P-selectin exposure in activated platelets. 26 These data indirectly implicate IKK in platelet secretion. To directly address this, platelets
were treated with BMS-345541 (5 μM, Figure 3A ) or TPCA-1 (0.5 μM; Supplemental Figure 4 ) stimulated with thrombin (0.05 U/mL) and release from dense granules, α-granules, and lysosomes was measured. Untreated platelets showed time-dependent release of cargo from all three granules.
Both IKKβ inhibitors blocked secretion by >70%. These data show that inhibition of IKKβ, using conditions that blocked SNAP-23 phosphorylation, affected release from dense granules, α-granules, and lysosomes.
To confirm the role of IKKβ, we generated a lineage-specific, IKKβ-deletion mouse strain by crossing IKKβ flox/fox mice with a strain containing a Platelet Factor 4 (PF4) promoter-driven Cre recombinase transgene. 29 Platelets from these mice had no detectable IKKβ ( Figure 3C ) and SNAP-23 phosphorylation at Ser95 was undetectable in thrombin-stimulated platelets ( Figure 3D ). As with the inhibitor-treated platelets, release from each class of granules was inhibited in IKKβ -/-platelets ( Figure   3B ). Platelet counts and granule cargo levels were unaffected (data not shown) and there was no overt effect on platelet morphology (Supplemental Figure 2B) indicating that loss of IKKβ had no effect on granule or platelet biogenesis. Further examination using lumi-aggregometry showed that release of ATP from dense granules in response to thrombin (0.05, 0.1 U/mL), collagen (10, 20 μg/mL), convulxin (0.1 μg/mL), PMA (200 nM) or A23187 (1 μM) was negatively affected by the loss of IKKβ. The effect on aggregation in response to these agonists was more variable but was generally attenuated (Supplemental Figure 5) . To further address the effects of SNAP-23 phosphorylation on SNARE complex formation, IKK was titrated into an in vitro fusion assay containing two types of proteoliposomes: VAMP-8-containing
Phosphorylation of SNAP-23
and SNAP-23/syntaxin-2-containing (syntaxin-2 is a surrogate for syntaxin-11). Fusion was monitored by fluorescence dequenching ( Figure 4F ). There was a dose-dependent increase in fusion rate which correlated with phosphorylation of SNAP-23 ( Figure 4F and G). Fusion did not occur when the tSNAREs were omitted (Supplemental Figure 4E) . The enhancement of fusion was dependent on IKK activity and was blocked by addition of either BMS-345541 or TPCA-1 (Supplemental Figure 6E and 6F). These data are consistent with the effects in intact platelets ( Figure 3 ) and demonstrate that IKK can directly affect SNARE complex formation and membrane fusion. In Figure 1 , the diacylglycerol (DAG) mimetic, PMA, stimulated SNAP-23 phosphorylation. To assess the importance of intra-platelet calcium, platelets were incubated with BAPTA/AM or EGTA prior to stimulation. Alternatively, intra-platelet calcium was mobilized with thapsigargin ( Figure 5A ). BAPTA/AM treatment dampened SNAP-23 phosphorylation while EGTA had little effect. Thapsigargin stimulated phosphorylation of Ser95. These data highlight the importance of intra-platelet calcium to SNAP-23 phosphorylation.
The role of kinases and phospholipases, known to be downstream of PAR-mediated platelet activation, were probed using selective inhibitors. Pre-treatment of platelets with the tyrosine kinase inhibitor, genistein (150 μM), a Src-family kinase inhibitor, PP2 (10 μM), or the Syk inhibitor, piceatannol (10 μM), had no effect on thrombin-stimulated SNAP-23 phosphorylation (Supplemental Figure 7) . Upon stimulation, phospholipase Cs generate IP 3 and DAG, which leads to PKC activation. U73122, a general PLC inhibitor, affected SNAP-23 phosphorylation; the inactive isomer U73343 did not ( Figure 5B ). To assess the role of PKC, we used three different PKC-selective inhibitors: RO-31-8220 (1 μM, pan-PKC,), Gö6976 (1 μM, PKC α/β-selective), and rottlerin (10 μM, PKC δ-selective). All three inhibitors affected thrombin-induced SNAP-23 phosphorylation implying a role for PKC ( Figure   5B ). These data show that PLC activation, DAG formation, calcium mobilization, and PKC activation are important for to SNAP-23 phosphorylation. Based on these results, it is not clear which PKC isoform plays a dominant role; this will require further investigation.
Our data, and that of others, suggest that either IKK or PKC could phosphorylate SNAP-23. 20 To clarify the order in which these kinases act, we determined whether PKC inhibitors affected IKK activation or whether IKK inhibitors affected PKC activation. IκB phosphorylation, as a metric of IKK activation, was monitored in platelets treated with PKC inhibitors (RO-31-8220, Gö6976, or rottlerin;
For personal use only. on October 4, 2017. by guest www.bloodjournal.org From Figure 5C ). All affected IκB phosphorylation, though none have been reported to affect IKKβ directly. or BMS-345541 (5 μM) and the total phospho-proteins were analyzed by SDS-PAGE and phosphorimaging ( Figure 5D ). Thrombin-mediated activation induced the phosphorylation of a major protein at ~47 kDa, which is pleckstrin, a PKC substrate. 40 As expected, RO-31-8220 (1 μM), blocked pleckstrin phosphorylation, but BMS-345541 (5 μM) had no effect. Under these conditions, the PKC inhibitor affected IKK activation but the IKKβ inhibitor had no effect on PKC activation. These data suggest that IKKβ is the SNARE-proximal kinase in the agonist-induced platelet signaling cascades.
Consistently, IKK, but not PKCα, phosphorylated Ser95 in vitro (Supplemental Figure 8 ).
Inhibiting IKKβ Affects Hemostasis:
To assess the physiological importance of IKK, we inhibited it pharmacologically or deleted it genetically in platelets and measured tail-bleeding times.
Pharmacokinetic studies of BMS-345541 indicated that it has a limited lifetime in the blood stream (t 1/2 = 2.2 hr) 35 , which we considered in our study design. The compound was administered by gavage at 10 mg/kg. After 2 hr, tail-bleeding-time measurements were made to assess the drug's effect on hemostasis. BMS-345541 treatment significantly prolonged bleeding times when compared to vehicletreated, control animals ( Figure 6A ). Consistently, analysis of the platelet-specific, IKKβ-deletion strain yielded similar results. The fact that these mice failed to clot normally shows that platelet IKKβ is important for hemostasis ( Figure 6B ). Activation of the NFκB/IκB/IKK pathway in response to platelet activation has been noted by several groups. 25, 26, 42, 43 However, IKK's role in platelets is controversial and no clear mechanism has been established. Using BAY-11-7082 and RO-106-9920, reports suggested a positive role for IKK in thrombin-or collagen-induced platelet aggregation, ATP release, TXA 2 formation, and P-selectin expression. 25, 26 Spinelli et al. 43 showed that BAY-11-7082 and SC-514 affected spreading but not aggregation. Conversely, Gambarayan et al. 42 suggested that IKK regulated PKA by disrupting a NFκB/IκB/PKA complex and thus acted as a negative regulator. Our data define a specific role for IKK.
Using three different IKKβ inhibitors (BMS-345541, TPCA-1, and BAY 11-7082) and tissue-specific knockout mice, we demonstrate a positive role for IKKβ in platelet secretion. Our analyses demonstrate that the IKKβ-mediated phosphorylation of SNAP-23 augments SNARE complex formation and membrane fusion. SNAP-23 phosphorylation is probably not the sole trigger for exocytosis given the modest effects on fusion seen in Figure 4F ; however, it appears to increase the efficacy of the process
and represents a key step. Defective platelet secretion (especially ADP) negatively affects platelet activation, thus our results offer explanations for some of the data in previous reports. 25, 26, 42, 43 Isoform-selective inhibitors of PKCα/β or δ affected SNAP-23 phosphorylation. This is consistent with our previous report showing that Ser95 on SNAP-23 was not phosphorylated in activated PKCα -/-platelets. 38 Our data imply that a PKC isoform is upstream of IKK, though it is unclear if that is true for all PKC isoforms. IKK inhibitors had no effect on phosphorylation of standard platelet, PKC substrates (i.e. plekstrin) but the PKC inhibitors blocked IKK activation. This relationship between PKC isoforms and IKK has been reported in other cell types (i.e. T-and B-cells) where PKC either directly or indirectly activates IKK. 44 Our data suggest that this aspect of platelet activation may be similar to what is found in other hematopoietic cells types. It is also striking to note that platelets contain several Toll-like Receptors (TLR) and are activated by TLR ligands. 45, 46 Given that IKK is downstream of TLRs 47 and platelets contain many of the signaling elements associated with TLR responses 45 , it seems plausible that IKK activation is a signaling node responsive to both hemostatic and innate immunity stimuli. to membranes. In a SNARE complex, this residue is distal to the SNARE transmembrane domain and thus distal to the forming fusion pore. If the SNARE domains zipper from N-to C-terminus, phosphoSer95 could initiate zippering. Alternatively it could be a spacer to separate formed SNARE complexes to orient fusion pore formation. Clearly a negative charge at that position is important since phosphomimetic mutations (Ser95-Glu/Asp) also enhance proteoliposome fusion (Zhang and Whiteheart unpublished). Structural studies will be required to assess the specific effects of Ser95 phosphorylation.
Finally, are IKK inhibitors potential anti-thrombotics? Burke et al. 35 showed that BMS-345541 is a selective inhibitor of IKKβ that affects NFκB-dependent transcription of cytokines in vitro and in vivo. reported the phenotype of IKKβ deficient platelets and showed that they were secretion deficient. mice were subjected to tail bleeding measurements. Each point represents the bleeding-time of a single animal. Statistical significance was determined by unpaired t-test using Sigma Plot software.
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